These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29090850)

  • 1. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.
    Tsukamoto H; Fujieda K; Senju S; Ikeda T; Oshiumi H; Nishimura Y
    Cancer Sci; 2018 Mar; 109(3):523-530. PubMed ID: 29090850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-related immunosuppression for cancer immunotherapy.
    Frumento G; Piazza T; Di Carlo E; Ferrini S
    Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):233-7. PubMed ID: 17017974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
    Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
    Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
    Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
    Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
    Hayakawa T; Yaguchi T; Kawakami Y
    Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoengineered targeting strategy for cancer immunotherapy.
    Yin WM; Li YW; Gu YQ; Luo M
    Acta Pharmacol Sin; 2020 Jul; 41(7):902-910. PubMed ID: 32398683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
    Becker Y
    Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment.
    Ma F; Vayalil J; Lee G; Wang Y; Peng G
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
    Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
    Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
    Bialkowski L; Van der Jeught K; Bevers S; Tjok Joe P; Renmans D; Heirman C; Aerts JL; Thielemans K
    Int J Cancer; 2018 Aug; 143(3):686-698. PubMed ID: 29464699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of IL-6 signaling in neuromyelitis optica.
    Araki M
    Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.